Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.32 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6922783 | 0.79 | ESRRG (0.37) | ESRRGKDM4EALDH1A1OPRD1 | |
| SCHEMBL15773064 | 0.71 | HTR2C (0.45) | — | |
| SCHEMBL6922776 | 0.71 | ALDH1A1 (0.38) | ESRRGKDM4EALDH1A1 | |
| SCHEMBL14590400 | 0.71 | BRD4 (0.41) | ESRRGSLC6A4KDM4EALDH1A1 | |
| SCHEMBL5341329 | 0.70 | HSP90AA1 (0.39) | ESRRGSLC6A4KDM4EALDH1A1SLC6A2 | |
| SCHEMBL434849 | 0.68 | ESRRG (0.55) | ESRRG | |
| SCHEMBL28601844 | 0.65 | LOXL2 (0.41) | KDM4E | |
| SCHEMBL5340820 | 0.65 | ESRRG (0.38) | ESRRG | |
| SCHEMBL9542839 | 0.65 | DRD2 (0.47) | — | |
| SCHEMBL15962305 | 0.64 | ADRB1 (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6740712-B2 | SILICON LINKERS BASED ON CARBAMYL PIPERAZINE MOIETY; USE IN SOLID PHASE SYNTHESIS OF COMPOUNDS OR LIBRARIES OF COMPOUNDS EMBRACING A PHENYL RING IN THEIR STRUCTURE | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-05-25 | — | — | US | disclosed |
| US-20020120072-A1 | Polymers based on N-carbamyl-N'-dimethysilyl methyl-piperazine traceless linkers for the solid phase synthesis of phenyl based libraries | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120072-A1 | Polymers based on N-carbamyl-N'-dimethysilyl methyl-piperazine traceless linkers for the solid phase synthesis of phenyl based libraries | DOT1L, DNMT3L, SMYD2 | ESRRG 4148/4885SLC6A4 2338/4885KDM4E 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.